On the heels of a first quarter sales dip, leaders remain confident in Globus Medical’s full-year success, according to a May 8 earnings call.
1. Globus Medical’s Excelsius robotic technologies are now compatible with the Reline Open, Modular, Mass, Mass Reduction, Small Stature, Mass Midline and Reline Cervical from NuVasive, CEO Dan Scavilla said, as transcribed by investing.com.
2. Robotic procedures with Globus Medical’s technologies grew 6% year over year, Mr. Scavilla said.
3. Although Globus Medical’s earnings were affected by temporary supply chain issues, CFO and COO Keith Pfeil said his long-term outlook was positive.
“As we move through 2025, this disruption will subside as integration supply chain challenges ease and restocking orders are placed to replenish orders filled at the end of 2024,” Mr. Pfeil said.
4. Mr. Pfeil said tariffs aren’t a major concern for the company.
“Overall, we do not see tariffs as materially impacting our business through supply chain disruptions or from a cost increase perspective,” he said. “Much of the Globus business is vertically integrated and predominantly U.S.-based, thus minimizing tariff exposure. Where we do see tariff impacts, we have launched a series of cost action offsets, including, but not limited to, targeted price increases, vendor resourcing and vendor cost renegotiations. We have actively and aggressively engaged on this initiative to ensure minimal impact to our business.”
